The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

9 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
2
Solid-phase synthesis of benzisothiazolones as serine protease inhibitors.EBI
Bristol Myers Squibb
1
Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate.EBI
Tokyo University of Pharmacy and Life Sciences
45
Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
23
Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
31
Synthesis of potent and selective 2-azepanone inhibitors of human tryptase.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
17
Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.EBI
Axys Pharmaceuticals
59
Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.EBI
Axys Pharmaceuticals
27
Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors.EBI
Yoshitomi Pharmaceutical Industries
13
Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics.EBI
Molecumetics